SCHEMBL8447494

SCHEMBL8447494

N[C@H](C(=O)O)[C@H](O)CC(=O)OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC15A1 P46059 2/20 0.59
SLC1A1 P43005 5/20 0.54
SLC1A3 P43003 4/20 0.54
SLC1A2 P43004 3/20 0.54
KMT2A Q03164 2/20 0.54
MEN1 O00255 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
ALDH1A1 P00352 4/20 0.53
MAPK1 P28482 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ABCB1 P08183 1/20 0.49
SLC6A2 P23975 1/20 0.45
SLC6A3 Q01959 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CDC25B P30305 1/20 0.44
LTA4H P09960 1/20 0.44
LAP3 P28838 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9781868 1.00 SLC15A1 (0.59) SLC15A1SLC1A1SLC1A3SLC1A2KMT2A
SCHEMBL27635124 1.00 SLC15A1 (0.59) SLC15A1SLC1A1SLC1A3SLC1A2KMT2A
SCHEMBL27713444 0.91 SLC15A1 (0.56) SLC15A1SLC1A1SLC1A3SLC1A2KMT2A
SCHEMBL6546883 0.83 ALDH1A1 (0.59) SLC15A1SLC1A1SLC1A3SLC1A2KMT2A
Hydrochloric Acid SCHEMBL27518479 0.83 ALDH1A1 (0.59) SLC15A1SLC1A1SLC1A3SLC1A2KMT2A
SCHEMBL22804119 0.83 SLC15A1 (0.65) SLC15A1SLC1A1SLC1A3SLC1A2KMT2A
SCHEMBL1241916 0.83 SLC15A1 (0.65) SLC15A1SLC1A1SLC1A3SLC1A2KMT2A
SCHEMBL4523936 0.82 SLC15A1 (0.65) SLC15A1SLC1A1SLC1A3SLC1A2KMT2A
SCHEMBL5898461 0.82 SLC15A1 (0.65) SLC15A1SLC1A1SLC1A3SLC1A2KMT2A
SCHEMBL730848 0.82 SLC15A1 (0.65) SLC15A1SLC1A1SLC1A3SLC1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-10-09 US disclosed
EP-4536653-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME Eisai R&D Management Co., Ltd. (JP) 2025-04-16 EP disclosed
US-20250002495-A1 SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) 2025-01-02 US disclosed
US-12157736-B2 Spiro-lactam NMDA modulators and methods of using same TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2024-12-03 US disclosed
US-20240300951-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-09-12 US disclosed
US-12084444-B2 Spiro-lactam NMDA modulators and methods of using same TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) 2024-09-10 US disclosed
US-20240270751-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-08-15 US disclosed
CN-117836296-A Pyrazolopyridone compounds 百济神州有限公司 2024-04-05 CN disclosed
WO-2024054919-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) 2024-03-14 WO disclosed
EP-3490994-B1 SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2024-02-07 EP disclosed
US-20180258139-A1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME NAUREX INC (US) 2018-09-13 US disclosed
US-9994614-B2 N-methyl-D-aspartate receptor modulators and methods of making and using same NAUREX, INC. (US) 2018-06-12 US disclosed
WO-2018026792-A1 SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC. (US) 2018-02-08 WO disclosed
US-20170210779-A1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME NAUREX INC (US) 2017-07-27 US disclosed
EP-3171941-A1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME Naurex Inc. (US) 2017-05-31 EP disclosed
WO-2016014982-A1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME NAUREX, INC. (US) 2016-01-28 WO disclosed
EP-0665229-B1 Process for the production of nucleic acid base derivatives AJINOMOTO KK (JP) 1999-11-17 EP disclosed
EP-0665229-A1 Process for the production of nucleic acid base derivatives Ajinomoto Co., Inc. (JP) 1995-08-02 EP disclosed
US-4500726-A IN PRESENCE OF PHASE TRANSFER AGENT PPG INDUSTRIES, INC. (US) 1985-02-19 US disclosed
US-4484001-A LIQUID PHASE BLOCKING OF AMINO ACIDS BY A BENZYL HALOFORMATE USING CROWN COMPOUND PHASE TRANSFER AGENTS PPG INDUSTRIES, INC. (US) 1984-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180258139-A1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME GRIN1, GRIN2A, GRIN3A SLC15A1 1260/4885SLC1A1 41/4885SLC1A3 51/4885
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME NEU1, NEU2, NEU4 SLC15A1 846/4885SLC1A1 267/4885SLC1A3 312/4885
US-20170210779-A1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME GRIN1, GRIN2A, GRIN3A SLC15A1 1260/4885SLC1A1 41/4885SLC1A3 51/4885
US-20240300951-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK SLC15A1 4547/4885SLC1A1 4726/4885SLC1A3 4818/4885
US-20240270751-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK SLC15A1 4547/4885SLC1A1 4726/4885SLC1A3 4818/4885
US-12084444-B2 Spiro-lactam NMDA modulators and methods of using same GRIN1, GRIN2A, GRIN2C SLC15A1 947/4885SLC1A1 42/4885SLC1A3 51/4885
US-20250002495-A1 SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME GRIN1, GRIN2A, GRIN2C SLC15A1 947/4885SLC1A1 42/4885SLC1A3 51/4885
US-12157736-B2 Spiro-lactam NMDA modulators and methods of using same GRIN1, GRIN2A, GRIN2C SLC15A1 947/4885SLC1A1 42/4885SLC1A3 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.